Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden

Blinatumomab Prior to CAR-T Cell Therapy—A Treatment Option Worth Consideration for High Disease Burden

The optimal bridging therapy before CAR-T cell infusion in pediatric relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL) still remains an open question. The administration of blinatumomab prior to CAR-T therapy is controversial since a potential loss of CD19+ target ce...

Full description

Bibliographic Details
Main Authors: Paweł Marschollek, Karolina Liszka, Monika Mielcarek-Siedziuk, Blanka Rybka, Renata Ryczan-Krawczyk, Anna Panasiuk, Igor Olejnik, Jowita Frączkiewicz, Iwona Dachowska-Kałwak, Agnieszka Mizia-Malarz, Tomasz Szczepański, Wojciech Młynarski, Jan Styczyński, Katarzyna Drabko, Grażyna Karolczyk, Ewa Gorczyńska, Jan Maciej Zaucha, Krzysztof Kałwak
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Biomedicines
Subjects:
blinatumomab
children
BCP-ALL
CAR-T cell therapy
bridging therapy
hematopoietic stem cell transplantation
Online Access:https://www.mdpi.com/2227-9059/10/11/2915

Similar Items

Similar Items